On Jun. 4, 2020, the FDA approved Merck’s Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired…
On Jun. 4, 2020, Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA)…
On Jun. 1, 2020, Gilead Sciences announced topline results from the Phase 3 SIMPLE trial in hospitalized patients…
On May 28, 2020, Roche announced it had initiated of a global phase III, randomised, double-blind, multicentre study…
On May 16, 2020, a single dose of ChAdOx1 nCoV-19, an investigational vaccine against SARS-CoV-2, has protected six…
On May 8, 2020, RedHill Biopharma announced the U.S. Food and Drug Administration (FDA) had approved its Investigational…
On Apr. 27, 2020, Mateon Therapeutics announced announced it has submitted an Investigational New Drug application to the…
On Apr. 27, 2020, BioAegis Therapeutics announced it had published gene expression data in animal studies where recombinant…
On Apr. 21, 2020, OpGen announced the start of an investigator initiated collaboration with Karolinska Institutet, Sweden, to…
On Apr. 20, 2020, RedHill Biopharma announced an agreement with the National Institute of Allergy and Infectious Diseases…
On Apr. 20, 2020, Alexion announced plans to initiate a global Phase 3 study to investigate ULTOMIRISﾮ (ravulizumab-cwvz)…
On Apr. 15, 2020, Humanigen announced that U.S. Food and Drug Administration (FDA) had given permission to commence…
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
On Apr. 6, 2020, Mateon Therapeutics announced an update on its rapid antiviral response program targeting coronaviruses, initially…
On Apr. 2, 2020, Novartis announced plans to initiate a phase III clinical trial in collaboration with Incyte…
On Apr. 2, 2020, BioAegis Therapeutics announced that it was preparing to evaluate plasma gelsolin replacement in severe…
On Mar. 30, 2020, Humanigen announced that the company had submitted an initial protocol synopsis to the FDA…
On Mar. 25, 2020, Mateon Therapeutics announced an update on its rapid antiviral response program targeting coronaviruses, initially…
On Mar. 24, 2020, City of Hope announced that it had employed its vast expertise using the immune…
On Mar. 23, 2020, Cumberland Pharmaceuticals announced a national initiative to support the treatment of patients with hospital-acquired…
On Mar. 20, 2020, a study was published in JAMA that expands the understanding of influenza-associated complications. Influenza…
On Mar. 19, 2020, Roche announced it was working with the U.S. Food & Drug Administration (FDA) to…
On Mar. 17, 2020, Israel’s Health Ministry announced that it had approved a request by Pluristem Therapeutics to…
On Mar. 9, 2020, MediciNova announced that it planned to initiate development of MN-166 (ibudilast) for severe pneumonia…
On Feb. 24, 2020, researchers reported that the spikes crowning the new coronavirus that causes COVID-19 atypical pneumonia…
On Jan. 23, 2020, the new cluster of viral pneumonia cases originating in Wuhan, China, marked the third…
On Jan. 9, 2020, the World Health Organization announced that a novel coronavirus had been identified as the…
On Dec. 19, 2019, the WHO announced that PNEUMOSIL, a vaccine against a leading cause of deadly childhood…
On Nov. 22, 2019, the Centers for Disease Control and Prevention”s (CDC) Advisory Committee on Immunization Practices (ACIP)…
On Sept. 27, 2016, the Region of the Americas was the first in the world to have eliminated…